Short Interest in Briacell Therap (NASDAQ:BCTX) Rises By 223.7%

Briacell Therap (NASDAQ:BCTX) saw a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 142,140 shares, an increase of 223.7% from the January 15th total of 43,910 shares. Currently, 2.1% of the company’s shares are sold short. Based on an average daily volume of 649,735 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 649,735 shares, the short-interest ratio is presently 0.2 days. Currently, 2.1% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Briacell Therap currently has a consensus rating of “Hold” and an average target price of $320.00.

Briacell Therap Trading Down 0.7%

Shares of BCTX stock opened at $4.21 on Thursday. The firm has a fifty day simple moving average of $6.97 and a two-hundred day simple moving average of $8.65. Briacell Therap has a 12 month low of $4.03 and a 12 month high of $98.20. The firm has a market capitalization of $30.52 million, a PE ratio of -0.10 and a beta of 1.42.

Briacell Therap (NASDAQ:BCTX) last issued its quarterly earnings data on Monday, December 15th. The company reported ($4.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($12.11) by $7.76. On average, equities analysts predict that Briacell Therap will post -2.45 earnings per share for the current fiscal year.

Institutional Trading of Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC acquired a new position in Briacell Therap (NASDAQ:BCTX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap as of its most recent SEC filing. 15.42% of the stock is owned by institutional investors and hedge funds.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.